TRIM13
Basic information
Region (hg38): 13:49995888-50020481
Previous symbols: [ "RFP2" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TRIM13 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 10 | 12 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 11 | 11 | ||||
Total | 0 | 0 | 21 | 2 | 0 |
Variants in TRIM13
This is a list of pathogenic ClinVar variants found in the TRIM13 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
13-50012085-C-G | not specified | Uncertain significance (Jan 29, 2024) | ||
13-50012194-T-C | not specified | Uncertain significance (Jan 23, 2023) | ||
13-50012244-C-T | not specified | Uncertain significance (Mar 02, 2023) | ||
13-50012269-T-C | not specified | Uncertain significance (Jun 09, 2022) | ||
13-50012273-G-T | not specified | Uncertain significance (Jun 17, 2024) | ||
13-50012289-T-G | not specified | Uncertain significance (Dec 21, 2023) | ||
13-50012419-G-A | not specified | Uncertain significance (Dec 22, 2023) | ||
13-50012478-G-C | not specified | Uncertain significance (Aug 08, 2023) | ||
13-50012501-G-T | not specified | Uncertain significance (May 04, 2023) | ||
13-50012581-C-T | not specified | Uncertain significance (May 18, 2022) | ||
13-50012760-G-A | not specified | Likely benign (Nov 21, 2022) | ||
13-50012824-A-G | not specified | Uncertain significance (Jan 08, 2024) | ||
13-50012858-C-G | not specified | Uncertain significance (Mar 25, 2024) | ||
13-50012950-A-G | not specified | Uncertain significance (Jun 07, 2024) | ||
13-50013004-G-C | not specified | Likely benign (Dec 21, 2022) | ||
13-50015518-T-G | not specified | Uncertain significance (Jan 03, 2024) | ||
13-50015537-T-C | not specified | Uncertain significance (Aug 17, 2022) | ||
13-50015581-C-T | not specified | Uncertain significance (Feb 27, 2024) | ||
13-50015606-G-A | not specified | Uncertain significance (Nov 02, 2021) | ||
13-50015624-T-C | not specified | Uncertain significance (Sep 28, 2022) | ||
13-50015701-C-G | not specified | Uncertain significance (Jul 14, 2022) | ||
13-50015726-A-G | not specified | Uncertain significance (Jun 29, 2022) | ||
13-50015767-C-T | not specified | Uncertain significance (Nov 02, 2023) | ||
13-50015822-T-G | not specified | Uncertain significance (Mar 18, 2024) | ||
13-50015843-G-A | not specified | Uncertain significance (May 26, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TRIM13 | protein_coding | protein_coding | ENST00000356017 | 2 | 24594 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.637 | 0.362 | 125702 | 0 | 31 | 125733 | 0.000123 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.939 | 176 | 215 | 0.820 | 0.0000106 | 2735 |
Missense in Polyphen | 46 | 86.424 | 0.53226 | 1150 | ||
Synonymous | -1.29 | 92 | 77.6 | 1.19 | 0.00000351 | 764 |
Loss of Function | 2.66 | 2 | 11.9 | 0.168 | 4.99e-7 | 177 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000348 | 0.000348 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000218 | 0.000217 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000986 | 0.0000967 |
Middle Eastern | 0.000218 | 0.000217 |
South Asian | 0.000105 | 0.0000980 |
Other | 0.000164 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Endoplasmic reticulum (ER) membrane anchored E3 ligase involved in the retrotranslocation and turnover of membrane and secretory proteins from the ER through a set of processes named ER-associated degradation (ERAD). This process acts on misfolded proteins as well as in the regulated degradation of correctly folded proteins. Enhances ionizing radiation-induced p53/TP53 stability and apoptosis via ubiquitinating MDM2 and AKT1 and decreasing AKT1 kinase activity through MDM2 and AKT1 proteasomal degradation. Regulates ER stress-induced autophagy, and may act as a tumor suppressor (PubMed:22178386). Plays also a role in innate immune response by stimulating NF-kappa-B activity in the TLR2 signaling pathway. Ubiquitinates TRAF6 via the 'Lys-29'-linked polyubiquitination chain resulting in NF-kappa-B activation (PubMed:28087809). Participates as well in T-cell receptor- mediated NF-kappa-B activation (PubMed:25088585). In the presence of TNF, modulates the IKK complex by regulating IKBKG/NEMO ubiquitination leading to the repression of NF-kappa-B (PubMed:25152375). {ECO:0000269|PubMed:17314412, ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22178386, ECO:0000269|PubMed:25088585, ECO:0000269|PubMed:25152375, ECO:0000269|PubMed:28087809}.;
- Pathway
- ER Quality Control Compartment (ERQC);Calnexin/calreticulin cycle;Post-translational protein modification;Metabolism of proteins;Asparagine N-linked glycosylation;N-glycan trimming in the ER and Calnexin/Calreticulin cycle
(Consensus)
Recessive Scores
- pRec
- 0.164
Intolerance Scores
- loftool
- 0.628
- rvis_EVS
- -0.36
- rvis_percentile_EVS
- 28.93
Haploinsufficiency Scores
- pHI
- 0.114
- hipred
- N
- hipred_score
- 0.444
- ghis
- 0.596
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.318
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Trim13
- Phenotype
Gene ontology
- Biological process
- anatomical structure morphogenesis;response to gamma radiation;positive regulation of cell death;positive regulation of macroautophagy;ubiquitin-dependent ERAD pathway;negative regulation of viral transcription;positive regulation of I-kappaB kinase/NF-kappaB signaling;proteasome-mediated ubiquitin-dependent protein catabolic process;innate immune response;positive regulation of NF-kappaB transcription factor activity;protein autoubiquitination;negative regulation of viral release from host cell;endoplasmic reticulum mannose trimming
- Cellular component
- endoplasmic reticulum membrane;integral component of membrane;endoplasmic reticulum quality control compartment;perinuclear endoplasmic reticulum
- Molecular function
- ubiquitin-protein transferase activity;protein binding;zinc ion binding;ubiquitin protein ligase activity